Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases including oncology and obesity, has announced its upcoming participation at the 43rd Annual J.P.

Rhea-AI Summary

Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases including oncology and obesity, has announced its upcoming participation at the 43rd Annual J.P. Morgan Healthcare Conference.

The company's management will deliver their presentation on January 15th, 2025, at 4:30 p.m. PT. Investors and interested parties can access a live webcast of the presentation through the investor relations page at http://ir.ternspharma.com. The presentation recording will remain available on the company's website for a minimum of 30 days following the event.

Argus Session date unavailable

-4.48% session move Open Argus

Details

News Market Reaction – TERN

The recorded move for TERN in the trading session of this news was -4.48%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43^rd Annual J.P. Morgan Healthcare Conference on January 15^th, 2025 at 4:30 p.m. PT.

A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Terns Pharmaceuticals (TERN) presenting at the 2025 J.P. Morgan Healthcare Conference?

Terns Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 15th, 2025, at 4:30 p.m. PT.

How can investors watch Terns Pharmaceuticals' (TERN) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available on Terns Pharmaceuticals' investor relations website at http://ir.ternspharma.com.

How long will Terns Pharmaceuticals' (TERN) J.P. Morgan presentation replay be available?

The presentation replay will be archived on Terns' website for at least 30 days following the presentation.

What therapeutic areas is Terns Pharmaceuticals (TERN) currently focusing on?

Terns Pharmaceuticals is developing small-molecule product candidates targeting serious diseases, including oncology and obesity.